The Cancer Letter recently published information regarding proton therapy facilities in the U.S., highlighting a contention that 85 percent of patients treated with protons have prostate cancer, the logical implication of which would be that this important resource is utilized minimally for other cancers. In this response, we wish to correct this erroneous impression and also wish to highlight the direction that this technology is moving in.
“We’ve always argued that money comes and goes, but if you lose a generation of scientists—you can’t buy them back,” said Kelvin Lee, director of the Indiana University Simon Comprehensive Cancer Center.
